for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jiangsu Hengrui Medicine Co Ltd

600276.SS

Latest Trade

100.50CNY

Change

-0.85(-0.84%)

Volume

25,083,124

Today's Range

98.59

 - 

101.35

52 Week Range

64.32

 - 

116.87

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
101.35
Open
100.18
Volume
25,083,124
3M AVG Volume
649.18
Today's High
101.35
Today's Low
98.59
52 Week High
116.87
52 Week Low
64.32
Shares Out (MIL)
5,331.72
Market Cap (MIL)
540,369.50
Forward P/E
83.09
Dividend (Yield %)
0.19

Next Event

Jiangsu Hengrui Medicine Co Ltd Annual Shareholders Meeting

Latest Developments

更多

Jiangsu Hengrui Medicine Agrees To Invest $20 Mln In Yingli Pharma For 6.67% Stake

Jiangsu Hengrui Medicine Says 9-Month Net Profit Up 14.0% Y/Y

Jiangsu Hengrui Medicine's H1 Net Profit Up 10.3% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jiangsu Hengrui Medicine Co Ltd

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.7 Kunlunshan Road

Lianyungang Eco & Tech Development Zone

LIANYUNGANG, JNG

222000

China

+86.518.81220983

http://www.hrs.com.cn

Executive Leadership

Yunshu Zhou

Chairman of the Board, General Manager

Song Zhou

Chief Financial Officer

Hongbin Dai

Deputy General Manager, Director

Jieping Sun

Deputy General Manager, Director

Lianshan Zhang

Deputy General Manager, Director

Key Stats

1.85 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

13.8K

2018

17.4K

2019

23.3K

2020(E)

28.5K
EPS (CNY)

2017

0.607

2018

0.764

2019

1.004

2020(E)

1.219
Price To Earnings (TTM)
80.31
Price To Sales (TTM)
20.98
Price To Book (MRQ)
15.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
22.56
Return on Equity (TTM)
19.96

Latest News

Latest News

China's blue-chip index extends gains on healthcare, financials boost

China's blue-chip index ended higher for the fourth straight session on Thursday, powered by healthcare, consumer staples and financials sectors, on investor optimism over swift recovery in the world's second-largest economy. ** At the close, the Shanghai Composite index...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up